Traws Pharma, Inc. (TRAW)
USD 1.5
(3.45%)
USD 1.5
(3.45%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -17.93 Million | -16.29 Million | -19.48 Million | -23.07 Million | -20.83 Million | -22.69 Million |
| Net Income | -18.94 Million | -18.96 Million | -16.16 Million | -25.15 Million | -21.5 Million | -20.57 Million |
| Depreciation & Amortization | 16 Thousand | 14 Thousand | 14 Thousand | 13 Thousand | 14 Thousand | 55 Thousand |
| Deferred income taxes | 437 Thousand | -98 Thousand | - | - | - | - |
| Stock-based compensation | 1.3 Million | 1.17 Million | 576 Thousand | 369 Thousand | - | - |
| Change in working capital | -301 Thousand | 1.48 Million | -3.59 Million | 1.49 Million | -327 Thousand | -1.06 Million |
| Other non-cash items | -437 Thousand | 98 Thousand | -321 Thousand | 208 Thousand | 844 Thousand | 429 Thousand |
| Investing Cash Flow | -14 Thousand | - | - | -15 Thousand | -55 Thousand | - |
| Investments in PPE | -14 Thousand | - | - | -15 Thousand | -55 Thousand | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | 55.56 Million | 19.35 Million | 26.64 Million | 35.65 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 55.04 Million | 9.06 Million | 26.64 Million | 35.65 Million |
| Other Financing Activities | - | - | - | - | - | - |
| Accounts receivables | 11 Thousand | -1000.00 | 9000.00 | 61 Thousand | -63 Thousand | 24 Thousand |
| Accounts payables | 1.75 Million | 1.1 Million | -2.07 Million | 562 Thousand | 232 Thousand | -1.45 Million |
| Inventory | -11 Thousand | 1000.00 | -9000.00 | -61 Thousand | - | - |
| Other working capital | -2.06 Million | 381 Thousand | -1.51 Million | 930 Thousand | -496 Thousand | 363 Thousand |
| Cash at beginning of period | 38.75 Million | 55.07 Million | 19.02 Million | 22.72 Million | 16.97 Million | 4.02 Million |
| Cash at end of period | 20.82 Million | 38.75 Million | 55.07 Million | 19.02 Million | 22.72 Million | 16.97 Million |
| Capital Expenditure | -14 Thousand | - | - | -15 Thousand | -55 Thousand | - |
| Effect of forex changes on cash | 10 Thousand | -19 Thousand | -28 Thousand | 32 Thousand | -6000.00 | - |
| Net cash flow / Change in cash | -17.93 Million | -16.31 Million | 36.04 Million | -3.7 Million | 5.75 Million | 12.94 Million |
| Free Cash Flow | -17.94 Million | -16.29 Million | -19.48 Million | -23.09 Million | -20.88 Million | -22.69 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -123.14 Million | -4.98 Million | -4.18 Million | -18.94 Million | -4.73 Million | -4.25 Million |
| Depreciation & Amortization | 4000.00 | 4000.00 | 4000.00 | 16 Thousand | 5000.00 | 4000.00 |
| Deferred income taxes | - | - | -869 Thousand | 437 Thousand | 706 Thousand | -106 Thousand |
| Stock-based compensation | 380 Thousand | 333 Thousand | 332 Thousand | 1.3 Million | 360 Thousand | 273 Thousand |
| Change in working capital | -4.55 Million | 222 Thousand | -582 Thousand | -301 Thousand | -95 Thousand | -517 Thousand |
| Other non-cash items | 118.24 Million | -608 Thousand | 869 Thousand | -437 Thousand | -706 Thousand | 106 Thousand |
| Investing Cash Flow | -3.64 Million | - | - | -14 Thousand | -14 Thousand | - |
| Investments in PPE | - | - | - | -14 Thousand | -14 Thousand | - |
| Acquisitions | -3.64 Million | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 13.99 Million | - | - | - | - | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 13.99 Million | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | - | - |
| Accounts receivables | - | - | - | 11 Thousand | -1000.00 | - |
| Accounts payables | -394 Thousand | 949 Thousand | -529 Thousand | 1.75 Million | 1.07 Million | 175 Thousand |
| Inventory | - | - | - | -11 Thousand | 1000.00 | - |
| Other working capital | -4.16 Million | -727 Thousand | -53 Thousand | -2.06 Million | -1.17 Million | -692 Thousand |
| Cash at beginning of period | 16.39 Million | 20.82 Million | 25.24 Million | 38.75 Million | 29.72 Million | 34.22 Million |
| Cash at end of period | 16.88 Million | 16.39 Million | 20.82 Million | 20.82 Million | 25.24 Million | 29.72 Million |
| Capital Expenditure | - | - | - | -14 Thousand | -14 Thousand | - |
| Effect of forex changes on cash | -3000.00 | -7000.00 | 7000.00 | 10 Thousand | -2000.00 | -1000.00 |
| Net cash flow / Change in cash | 496 Thousand | -4.43 Million | -4.42 Million | -17.93 Million | -4.48 Million | -4.49 Million |
| Free Cash Flow | -9.85 Million | -4.42 Million | -4.43 Million | -17.94 Million | -4.48 Million | -4.49 Million |
YAK
ASSAMENT
RANEHOLDIN
SWEC-A
INN
BIOCON